Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Kazuoki, Kondo"'
Autor:
Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 17, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/19fa0a9f69874c2db3a458026de01630
Autor:
Hitoshi Tajiri, Katsuhiro Arai, Seiichi Kagimoto, Reiko Kunisaki, Nobuyuki Hida, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
BMC Pediatrics, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Pediatric ulcerative colitis (UC) is typically more extensive and has a more active disease course than adult UC, and requires early treatment augmentation to achieve and maintain disease remission. The present study aimed to inve
Externí odkaz:
https://doaj.org/article/fef5f15419144eb68e03c0bd5d6c6e42
Autor:
Jun Horiguchi, Koichiro Watanabe, Kazuoki Kondo, Atsushi Iwatake, Hajime Sakamoto, Yutaka Susuta, Hideaki Masui, Yumi Watanabe
Publikováno v:
Psychiatry and Clinical Neurosciences. 76:560-569
Valbenazine is approved in the US for treatment of tardive dyskinesia (TD); however, efficacy/safety data in Asian populations are lacking. We assessed the efficacy/safety of valbenazine in Japanese patients.This phase II/III, multicenter, randomized
Autor:
Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201956 (2018)
OBJECTIVES:The prevalence of pediatric Crohn's disease (CD) is increasing in Japan and other countries, and many patients are unresponsive to or do not tolerate current treatment options. This study aimed to investigate the efficacy, safety, and phar
Externí odkaz:
https://doaj.org/article/54495b6afda746d38c11181a383b9c27
Autor:
Kazuoki Kondo, Yoshinobu Nakamaru, Manabu Hirai, Yukiko Nishimura, Kaori Yoshida, Munetomo Matsuda, Yuichiro Kato, Hidetoshi Shimizu, Youichi Shiide
Publikováno v:
Clinical Pharmacology in Drug Development
The neuroprotective agent edaravone is an intravenous treatment for amyotrophic lateral sclerosis. As intravenous administration burdens patients, orally administered treatments are needed. This phase 1, open‐label, single‐dose crossover study in
Autor:
Kazuoki Kondo, Yukiko Nishimura, Yuichiro Kato, Yoshinobu Nakamaru, Hidetoshi Shimizu, Hideaki Matsuda, Yoichi Shiide, Makoto Akimoto, Munetomo Matsuda
Publikováno v:
Clinical Pharmacology in Drug Development
Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formu
Autor:
Genki Kaneko, Hiroki Matsuda, Yoshimasa Kokado, Yutaka Kawaguchi, Kiichiro Ueta, Masaomi Nangaku, Kazuoki Kondo, Yasuhiro Komatsu
Publikováno v:
Nephrology Dialysis Transplantation
Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. Methods The efficacy and safety of vadadustat, compared with darbepoetin alfa, was determined in a Phase 3 double-blind study in Ja
Publikováno v:
Clinical Therapeutics. 42:1699-1714
Purpose The goal of this study was to compare edaravone pharmacokinetic (PK) variables and tolerability after a single intravenous (IV) infusion of 30 mg over 60 min in subjects with mild renal impairment (estimated glomerular filtration rate 60–89
Autor:
Hidetoshi Shimizu, Kaori Yoshida, Makoto Akimoto, Tomoko Natori, Shinsuke Inoue, Mai Endo, Kazuoki Kondo, Masae Kakubari, Yoshinobu Nakamaru
Publikováno v:
Clinical Pharmacology in Drug Development
This randomized, single‐blind, 3‐way crossover study assessed the effect of edaravone on QT interval, including an exposure‐response analysis. Twenty‐seven healthy Japanese male volunteers, aged 20 to 49 years, were randomly assigned to recei
Autor:
Kazuoki Kondo, Yasuhiro Komatsu, Genki Kaneko, Yoshimasa Kokado, Yutaka Kawaguchi, Kiichiro Ueta, Masaomi Nangaku, Tsubasa Tandai
Publikováno v:
J Am Soc Nephrol
Background Standard care for treating anemia in patients with CKD includes use of erythropoiesis-stimulating agents, which sometimes involves increased risks of cardiovascular morbidity and mortality. Previous studies in patients with anemia and nond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348eaabd405fdbb475ed2a3bf1e081be
https://europepmc.org/articles/PMC8425651/
https://europepmc.org/articles/PMC8425651/